Monitoring therapeutic monoclonal antibodies in brain tumor

No abstract is available for this paper.

• Publication year

  2014

• Venue

  mAbs

• Publication date

  2014-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.4161/mabs.34405PMID 25484065PMCID PMC4622724
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

  2014cited by this paper
• Top Down proteomics: facts and perspectives.

  2014cited by this paper
• 9th Annual European Antibody Congress, November 11–13, 2013, Geneva, Switzerland

  2014cited by this paper
• Antibodies to watch in 2014

  2014cited by this paper
• Detailed mass analysis of structural heterogeneity in monoclonal antibodies using native mass spectrometry

  2014cited by this paper
• MALDI imaging and in‐source decay for top‐down characterization of glioblastoma

  2014cited by this paper
• Emerging antiangiogenics for renal cancer

  2013cited by this paper
• Characterization of therapeutic antibodies and related products.

  2013cited by this paper
• Tubulin isoforms identified in the brain by MALDI in-source decay.

  2013cited by this paper
• Selected protein monitoring in histological sections by targeted MALDI-FTICR in-source decay imaging.

  2013cited by this paper
• Bevacizumab for the Treatment of Glioblastoma

  2013cited by this paper
• Protein digestion: an overview of the available techniques and recent developments.

  2013cited by this paper
• A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies

  2012cited by this paper
• Antiangiogenic Therapy for Glioma

  2012cited by this paper
• Mass spectrometry imaging is moving toward drug protein co-localization.

  2012cited by this paper
• Monoclonal antibodies in neuro-oncology

  2011cited by this paper
• N-terminal Glutamate to Pyroglutamate Conversion in Vivo for Human IgG2 Antibodies

  2011cited by this paper
• Advances in top-down proteomics for disease biomarker discovery.

  2011cited by this paper
• Matrix sublimation/recrystallization for imaging proteins by mass spectrometry at high spatial resolution.

  2011cited by this paper
• The Blood-Brain Barrier in Brain Tumours

  2011cited by this paper
• MALDI-in source decay applied to mass spectrometry imaging: a new tool for protein identification.

  2010cited by this paper
• Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion

  2010cited by this paper
• Fine Mapping the Spatial Distribution and Concentration of Unlabeled Drugs within Tissue Micro-Compartments Using Imaging Mass Spectrometry

  2010cited by this paper
• The VEGF family in cancer and antibody-based strategies for their inhibition

  2010cited by this paper
• Discrimination of isobaric leucine and isoleucine residues and analysis of post-translational modifications in peptides by MALDI in-source decay mass spectrometry combined with collisional cooling.

  2010cited by this paper
• Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections

  2010cited by this paper
• Direct molecular analysis of whole-body animal tissue sections by MALDI imaging mass spectrometry.

  2010cited by this paper
• Strategies and challenges for the next generation of therapeutic antibodies

  2010cited by this paper
• To protect peptide pharmaceuticals against peptidases.

  2010cited by this paper
• Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

  2009cited by this paper
• Importance and limitations of chemotherapy among the available treatments for gastrointestinal tumours.

  2009cited by this paper
• Bevacizumab: current indications and future development for management of solid tumors.

  2009cited by this paper
• Imaging mass spectrometry for the assessment of drugs and metabolites in tissue.

  2009cited by this paper
• A history of cancer chemotherapy.

  2008cited by this paper
• Paclitaxel Plus Bevacizumab Versus Paclitaxel Alone for Metastatic Breast Cancer

  2008cited by this paper
• Molecular imaging of proteins in tissues by mass spectrometry

  2008cited by this paper
• Characterization of variable regions of monoclonal antibodies by top-down mass spectrometry.

  2007cited by this paper
• Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.

  2007cited by this paper
• Mapping pharmaceuticals in tissues using MALDI imaging mass spectrometry.

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Penetration of bevacizumab through the retina after intravitreal injection in the monkey.

  2007cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery

  2005cited by this paper
• Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

  2005cited by this paper
• Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells.

  2004cited by this paper
• Protein Identification by Mass Spectrometry

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention.

  2003cited by this paper
• The biology of VEGF and its receptors

  2003cited by this paper
• T3-sequencing: targeted characterization of the N- and C-termini of undigested proteins by mass spectrometry.

  2003cited by this paper
• N-Cα bond cleavage of the peptide backbone via hydrogen abstraction

  2001cited by this paper
• Journal of The American Society for Mass Spectrometry

  1997cited by this paper
• Discrimination effects and sensitivity variations in matrix‐assisted laser desorption/ionization

  1997cited by this paper
• Effects of cellular pharmacology on drug distribution in tissues.

  1995cited by this paper
• Monitoring of IgG antibody thermal stability by micellar electrokinetic capillary chromatography and matrix-assisted laser desorption/ionization mass spectrometry.

  1995cited by this paper
• Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients.

  1995cited by this paper
• A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.

  1990cited by this paper
• Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection.

  1989cited by this paper
• Distribution of immunoglobulin on the surface of mouse lymphoid cells as determined by immunoferritin electron microscopy, Antibody‐induced, temperature‐dependent redistribution and its implications for membrane structure

  1972cited by this paper

• Distribution of Bevacizumab into the Cerebrospinal Fluid of Children and Adolescents with Recurrent Brain Tumors

  2024cites this paper
• Suborgan Level Quantitation of Proteins in Tissues Delivered by Polymeric Nanocarriers.

  2024cites this paper
• Multiplexed Quantitative Screening of the Cellular Uptake of Proteins Delivered by Polymeric Nanocarriers.

  2024cites this paper
• Mapping the human brain proteome: opportunities, challenges, and clinical potential

  2024cites this paper
• Immunotherapy for colorectal cancer: Rational strategies and novel therapeutic progress.

  2023cites this paper
• Identification and validation of basic fibroblast growth factor as a prognostic biomarker for the response of lung adenocarcinoma patients to bevacizumab treatment.

  2023cites this paper
• Post-translational modifications and glycoprofiling of palivizumab by UHPLC–RPLC/HILIC and mass spectrometry

  2022cites this paper
• Spatial analysis of drug absorption, distribution, metabolism, and toxicology using Mass Spectrometry Imaging.

  2022cites this paper
• An Overview of Brain Tumor

  2022cites this paper
• Emerging applications in mass spectrometry imaging; enablers and roadblocks

  2020cites this paper
• Advanced MALDI mass spectrometry imaging in pharmaceutical research and drug development.

  2019cites this paper
• Digital Image Analysis in Clinical and Experimental Pathology

  2019cites this paper
• Structural Analysis of Monoclonal Antibodies by Ultrahigh Resolution MALDI In-Source Decay FT-ICR Mass Spectrometry

  2018cites this paper
• MALDI-MSI of Immunotherapy: Mapping the EGFR-Targeting Antibody Cetuximab in 3D Colon-Cancer Cell Cultures.

  2018cites this paper
• Clinical applications of MALDI imaging technologies in cancer and neurodegenerative diseases.

  2017cites this paper
• Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies

  2017cites this paper
• Mass Spectrometry Imaging in Nanomedicine: Unraveling the Potential of MSI for the Detection of Nanoparticles in Neuroscience.

  2017cites this paper
• Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors

  2017cites this paper
• Label-free quantification of peptides in solution by disposable patterned hydrophilic chip based MALDI imaging

  2016cites this paper
• Apports de l'échange hydrogène/deutérium couplé à la spectrométrie de masse en protéomique structurale pour la caractérisation de complexes multi-protéiques.

  2016cites this paper
• Mass spectrometry-based approaches for quality control and quantification of monoclonal antibodies

  2016cites this paper
• Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates

  2016cites this paper